Id: acc4426
Group: 1sens
Protein: p70S6K
Gene Symbol: RPS6KB1
Protein Id: P23443
Protein Name: KS6B1_HUMAN
PTM: phosphorylation
Site: unclear
Site Sequence:
Disease Category: Cancer
Disease: Cancer
Disease Subtype:
Disease Cellline: HCT116?
Disease Info:
Drug: Ascochlorin?
Drug Info: Ascochlorin is a drug that may have certain biological activities and potential medicinal applications.
Effect: modulate
Effect Info: "Ascochlorin inhibits ERK phosphorylation, thereby inducing G1 phase arrest by downregulating c - Myc and suppressing cancer cell proliferation."
Note:
Score: 4.0
Pubmed(PMID): 28833404
Sentence Index:
Sentence:

Sequence & Structure:

MRRRRRRDGFYPAPDFRDREAEDMAGVFDIDLDQPEDAGSEDELEEGGQLNESMDHGGVGPYELGMEHCEKFEISETSVNRGPEKIRPECFELLRVLGKGGYGKVFQVRKVTGANTGKIFAMKVLKKAMIVRNAKDTAHTKAERNILEEVKHPFIVDLIYAFQTGGKLYLILEYLSGGELFMQLEREGIFMEDTACFYLAEISMALGHLHQKGIIYRDLKPENIMLNHQGHVKLTDFGLCKESIHDGTVTHTFCGTIEYMAPEILMRSGHNRAVDWWSLGALMYDMLTGAPPFTGENRKKTIDKILKCKLNLPPYLTQEARDLLKKLLKRNAASRLGAGPGDAGEVQAHPFFRHINWEELLARKVEPPFKPLLQSEEDVSQFDSKFTRQTPVDSPDDSTLSESANQVFLGFTYVAPSVLESVKEKFSFEPKIRSPRRFIGSPRTPVSPVKFSPGDFWGRGASASTANPQTPVEYPMETSGIEQMDVTMSGEASAPLPIRQPNSGPYKKQAFPMISKRPEHLRMNL

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
RPS6KB1 TAS0612 Ribosomal protein S6 kinase (P70S6K) inhibitor 1 Recruiting neoplasm ClinicalTrials
RPS6KB1 MSC-2363318A Ribosomal protein S6 kinase (P70S6K) inhibitor 1 Completed neoplasm ClinicalTrials
RPS6KB1 LY-2780301 Ribosomal protein S6 kinase (P70S6K) inhibitor 1 Completed lymphoma ClinicalTrials
RPS6KB1 XL-418 Ribosomal protein S6 kinase (P70S6K) inhibitor 1 Suspended neoplasm ClinicalTrials
RPS6KB1 LY-2584702 Ribosomal protein S6 kinase 1 inhibitor 1 Terminated renal cell carcinoma ClinicalTrials
RPS6KB1 LY-2584702 Ribosomal protein S6 kinase 1 inhibitor 1 Terminated non-small cell lung carcinoma ClinicalTrials
RPS6KB1 LY-2584702 Ribosomal protein S6 kinase 1 inhibitor 1 Terminated metastasis ClinicalTrials
RPS6KB1 LY-2780301 Ribosomal protein S6 kinase (P70S6K) inhibitor 1 Completed metastasis ClinicalTrials
RPS6KB1 LY-2584702 Ribosomal protein S6 kinase 1 inhibitor 1 Terminated neuroendocrine neoplasm ClinicalTrials
RPS6KB1 LY-2584702 Ribosomal protein S6 kinase 1 inhibitor 1 Completed cancer ClinicalTrials
RPS6KB1 LY-2584702 Ribosomal protein S6 kinase 1 inhibitor 1 Terminated cancer ClinicalTrials
RPS6KB1 XL-418 Ribosomal protein S6 kinase (P70S6K) inhibitor 1 Suspended cancer ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

RPS6KB1-Ser371
Cancer Intensity
BRCA
COAD -0.707
HGSC
ccRCC 0.707
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RPS6KB1-Ser375
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.707
GBM
HNSC -0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RPS6KB1-Ser418
Cancer Intensity
BRCA -0.189
COAD 0.616
HGSC 1.605
ccRCC -2.354
GBM -0.189
HNSC 0.25
LUAD 0.135
LUSC 0.115
non_ccRCC
PDAC -0.404
UCEC 0.416
RPS6KB1-Ser424
Cancer Intensity
BRCA -0.557
COAD 1.149
HGSC 1.838
ccRCC -1.833
GBM 0.084
HNSC 0.253
LUAD -0.453
LUSC -0.048
non_ccRCC
PDAC -0.577
UCEC 0.145
RPS6KB1-Ser429
Cancer Intensity
BRCA -0.199
COAD
HGSC 1.767
ccRCC
GBM -0.531
HNSC
LUAD
LUSC -0.418
non_ccRCC
PDAC
UCEC -0.618
RPS6KB1-Thr376
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.707
GBM
HNSC -0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RPS6KB1-Thr389
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.707
GBM -0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RPS6KB1-Thr421
Cancer Intensity
BRCA -1.122
COAD 1.552
HGSC
ccRCC -1.395
GBM -0.379
HNSC 0.47
LUAD -0.284
LUSC 0.124
non_ccRCC
PDAC -0.319
UCEC 1.351

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
- - P Ameloblastoma Phosphorylation 22977662
- - U Chronic myelogenous leukemia/chronic myeloid leukemia Phosphorylation 23384908
- - U Lung adenocarcinoma Phosphorylation 23934262
- - U Hepatocellular carcinoma/hepatocarcinoma/hepatoma Phosphorylation 23934262
- - U Breast cancer/tumor/carcinoma Phosphorylation 24023352
- - U Gallbladder cancer Phosphorylation 24124380
- - U Non-small cell lung cancer/carcinoma Phosphorylation 23886172
- - U Osteogenic sarcoma/osteosarcoma Phosphorylation 23879172
- - U Breast cancer/tumor/carcinoma Phosphorylation 23794518

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: